98%
921
2 minutes
20
Background And Objectives: Prior research has shown that temporary deferrals negatively influence donor return rates, but it remains unknown the extent to which these effects vary across reasons for deferral. We investigate whether deferrals differ in their degree of perceived stigmatization and, if so, how being deferred for stigmatizing (vs. non-stigmatizing) reasons affects subsequent donation behaviour.
Materials And Methods: We examined whether reasons for deferral vary on their perceived level of stigmatization through an online survey (n = 400). Furthermore, we used a dataset encompassing 25 years of donation records from the state-run blood collection agency (BCA) from Rio de Janeiro, Brazil, to investigate how stigmatizing (vs. non-stigmatizing) reasons for deferral affected return rates of 82,648 donors over a 60-month follow-up period.
Results: Being deferred for sex- and drug-related reasons was perceived as much more stigmatizing than other reasons for deferral (odds ratio = 3.14, 95% confidence interval [CI]: 2.33-4.25). Controlling for multiple observables, prospective donors were less likely to return to the BCA when deferred for stigmatizing (vs. non-stigmatizing) reasons (adjusted hazard ratio = 0.87, 95% CI: 0.83-0.93).
Conclusion: Donors perceive deferrals motivated by sex- and drug-related reasons as particularly stigmatizing, which is negatively associated with donor return rates. BCAs may want to pay special attention when communicating stigmatizing reasons for deferral to prospective donors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/vox.13607 | DOI Listing |
Asian J Transfus Sci
December 2022
Department of Immunohematology and Blood Transfusion, ESIC Model Hospital, New Delhi, India.
Background: Blood transfusion is an integral part of the health-care system. A healthy donor is important for safe blood transfusion. Donors are selected based on the deferral criteria given by the Drugs and Cosmetics Act 1940 and amended thereof.
View Article and Find Full Text PDFBMC Infect Dis
August 2025
Instituto Nacional de Saúde, Marracuene, Mozambique.
Background: Blood transfusion is essential in modern medicine, but transfusion of blood may present for both the blood donor as well as the recipient risks. Strategies such as pre-interview (including clinical assessment) of donors and the subsequent testing of donated blood for infectious agents are steps taken to guarantee blood transfusion safety. The information about the reasons for deferring blood donors is not only important for improving the availability of blood, but also for actions to improve the health of the population in general.
View Article and Find Full Text PDFGait Posture
July 2025
Division of Pediatric Orthopedics, Department of Orthopedic Surgery, Chang Gung Memorial Hospital - Linkou, Taoyuan, Taiwan; Motion Analysis Laboratory, Bone and Joint Research Center, Chang Gung Memorial Hospital - Linkou, Taoyuan, Taiwan. Electronic address:
Background: Orthopedic surgery is commonly used to slow the progressive deterioration of body structure and motor function in children with cerebral palsy (CP). While parents may delay surgery for non-medical reasons, concerns about functional decline persist. However, limited data exist to guide informed decision-making.
View Article and Find Full Text PDFPediatr Pulmonol
July 2025
Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Background: Despite eligibility of over 90% of people with cystic fibrosis (PwCF) for CFTR modulators, 12% of eligible PwCF are not prescribed these therapies. The CF Foundation CF Learning Network (CFLN) convened a quality improvement (QI) innovation lab (iLab) to investigate gaps in modulator use and identify best practices for modulator initiation, management, and side effect screening.
Methods: Thirty-one CF centers used the Model for Improvement to adapt interventions to local context by Plan-Do-Study-Act cycles and approach aims in two phases: (1) increase documented elexacaftor-tezacaftor-ivacaftor or ivacaftor (ETI/I) use or co-produced deferral by 4% by 5/2023 and (2) increase side effect screening rates for PwCF taking ETI to 80% by 8/2024.
Urology
June 2025
Department of Urology, Mayo Clinic Arizona, Phoenix, AZ.
Objective: To assess how financial toxicity may impact the risk of deferral of recommended therapy in nephrolithiasis patients.
Methods: We performed a nationwide cross-sectional survey of adult volunteers with kidney stone disease registered with ResearchMatch. Comprehensive Score for Financial Toxicity (COST-FACIT) score <21 was used to identify patients with nephrolithiasis-related financial toxicity.